Anti-Biofilm Effect of Bacteriophages and Antibiotics against Uropathogenic Escherichia coli .
Laima MukaneKarlis RacenisDace RezevskaAivars PetersonsJuta KroicaPublished in: Antibiotics (Basel, Switzerland) (2022)
Escherichia coli is a common cause of biofilm-associated urinary tract infections. Bacteria inside the biofilm are more resistant to antibiotics. Six E. coli strains isolated from patients with urinary tract infections were screened for biofilm-forming capability and antimicrobial susceptibility. Two of the most significant biofilm-producing strains were selected for minimal inhibitory concentration and minimal biofilm eradication concentration in vitro testing using amoxicillin-clavulanic acid, ciprofloxacin, and three commercial bacteriophage cocktails (Pyobacteriophag, Ses, and Intesti). In case of a low phage effect, an adaptation procedure was performed. Although the biofilms formed by strain 021UR were resistant to amoxicillin-clavulanic acid and ciprofloxacin, the three phage cocktails were able to reduce biofilm formation. In contrast, phages did not affect the 01206UR strain against planktonic and biofilm-forming cells. After Pyobacteriophag adaptation, the effect improved, and, regardless of the concentration, the adapted phage cocktail could destroy both planktonic cells and the biofilm of strain 01206UR. Bacteriophages capable of killing bacteria in biofilms can be used as an alternative to antibiotics. However, each case should be considered individually due to the lack of clinical trials for phage therapy. Antimicrobial and phage susceptibility should be determined in biofilm models before treatment to achieve the desired anti-biofilm effect.
Keyphrases
- pseudomonas aeruginosa
- biofilm formation
- escherichia coli
- candida albicans
- staphylococcus aureus
- cystic fibrosis
- urinary tract infection
- clinical trial
- stem cells
- induced apoptosis
- magnetic resonance imaging
- oxidative stress
- bone marrow
- computed tomography
- randomized controlled trial
- minimally invasive
- klebsiella pneumoniae
- study protocol
- contrast enhanced
- cell proliferation
- combination therapy
- signaling pathway